Cargando…
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
Autores principales: | Blache, Ulrich, Popp, Georg, Dünkel, Anna, Koehl, Ulrike, Fricke, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445013/ https://www.ncbi.nlm.nih.gov/pubmed/36064867 http://dx.doi.org/10.1038/s41467-022-32866-0 |
Ejemplares similares
Ejemplares similares
-
CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023) -
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
por: Blache, Ulrich, et al.
Publicado: (2021) -
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022) -
Production and Application of CAR T Cells: Current and Future Role of Europe
por: Vucinic, Vladan, et al.
Publicado: (2021) -
CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)